The role of HLA-DQ heterodimers in patients mismatched for 1 HLA-DQ molecule
| Feature . | Population . | Clinical endpoint . | Genotype or mismatch* . | Patients, n . | Hazard ratio (95% CI; P value)† . |
|---|---|---|---|---|---|
| Patient genotype | Patients with 1 HLA-DQ-mismatch | Relapse | G1G1 | 26 | 1.0 |
| G1G2 | 220 | 2.85 (1.14-7.12; .02) | |||
| G2G2 | 20 | 1.81 (0.53-6.11; .34) | |||
| Disease-free survival | G1G1 | 32 | 1.0 | ||
| G1G2 | 263 | 1.64 (1.00-2.69; .05) | |||
| G2G2 | 21 | 1.57 (0.76-3.23; .23) | |||
| Patient mismatch | Patients with 1 HLA-DQ-mismatch | Relapse | G1G1 | 26 | 1.0 |
| G1G2 | 119 | 2.48 (0.98-6.29; .06) | |||
| G1G2 | 101 | 3.25 (1.27-8.33; .01) | |||
| G2G2 | 20 | 1.76 (0.53-5.86; .36) | |||
| Disease-free survival | G1G1 | 32 | 1.0 | ||
| G1G2 | 142 | 1.50 (0.90-2.49; .12) | |||
| G1G2 | 121 | 1.69 (1.01-2.84; .05) | |||
| G2G2 | 21 | 1.43 (0.70-2.90; .33) |
| Feature . | Population . | Clinical endpoint . | Genotype or mismatch* . | Patients, n . | Hazard ratio (95% CI; P value)† . |
|---|---|---|---|---|---|
| Patient genotype | Patients with 1 HLA-DQ-mismatch | Relapse | G1G1 | 26 | 1.0 |
| G1G2 | 220 | 2.85 (1.14-7.12; .02) | |||
| G2G2 | 20 | 1.81 (0.53-6.11; .34) | |||
| Disease-free survival | G1G1 | 32 | 1.0 | ||
| G1G2 | 263 | 1.64 (1.00-2.69; .05) | |||
| G2G2 | 21 | 1.57 (0.76-3.23; .23) | |||
| Patient mismatch | Patients with 1 HLA-DQ-mismatch | Relapse | G1G1 | 26 | 1.0 |
| G1G2 | 119 | 2.48 (0.98-6.29; .06) | |||
| G1G2 | 101 | 3.25 (1.27-8.33; .01) | |||
| G2G2 | 20 | 1.76 (0.53-5.86; .36) | |||
| Disease-free survival | G1G1 | 32 | 1.0 | ||
| G1G2 | 142 | 1.50 (0.90-2.49; .12) | |||
| G1G2 | 121 | 1.69 (1.01-2.84; .05) | |||
| G2G2 | 21 | 1.43 (0.70-2.90; .33) |